All the sequences generated in this study were deposited in GenBank with accession numbers KU843606-KU843834.

Introduction {#sec001}
============

Human Pegivirus (HPgV, formerly GBV-C/HGV), a positively single stranded RNA virus of the genus *Pegivirus* (family: *Flaviviridae*) \[[@pone.0161880.ref001]\], which is the most prevalent non-pathogenic RNA virus worldwide \[[@pone.0161880.ref002]\], has been reported to be associated with reduced morbidity and mortality in HIV-infected individuals \[[@pone.0161880.ref003]--[@pone.0161880.ref006]\]. The mechanisms by which HPgV modulated HIV infection include direct interference with HIV entry and replication and indirect regulation of host factors that can ameliorate disease progression \[[@pone.0161880.ref007], [@pone.0161880.ref008]\]. Due to the shared transmission routes, namely through sexual contact \[[@pone.0161880.ref009], [@pone.0161880.ref010]\], blood donation \[[@pone.0161880.ref011]\] and intravenous drug usage\[[@pone.0161880.ref012]\], co-infection with HPgV is common among people infected with HIV-1. Relatively high incidence of co-infections with HPgV (≈ 37%) have been reported in the HIV infected subjects in the Hubei province of China \[[@pone.0161880.ref013]\]. Phylogenetically, HPgV has been classified into five genotypes (genotypes 1--5) \[[@pone.0161880.ref012], [@pone.0161880.ref014]\], and genotype 3 is reported to be predominant in China \[[@pone.0161880.ref013], [@pone.0161880.ref015]--[@pone.0161880.ref017]\]. Despite the presence of HIV, HPgV strains belonging to genotype 3 have been reported to exhibit remarkable population growth within each co-infected host and the E1-E2 genomic regions of HPgV experienced intense purifying selection \[[@pone.0161880.ref013]\]. Despite these facts, little is known about the forces that contribute to such high genetic diversity of HPgV within the HIV co-infected patients.

Genetic recombination, which is an important evolutionary mechanism in RNA viruses \[[@pone.0161880.ref018]--[@pone.0161880.ref023]\], is known to be the major driving force in maintaining high genetic diversity in HPgV \[[@pone.0161880.ref024]--[@pone.0161880.ref026]\]. However, it is unclear to what extent such genetic recombination contributes in maintaining high genetic diversity in HIV infected hosts and whether such viral diversity patterns within each individual are gender-biased. Utilizing the HPgV E1-E2 sequence data from the HIV-HPgV co-infected patients residing in the Hubei province of China, the objective of the present study was to investigate the role of recombination on genetic diversity within each patient, and further to explore whether a patient's gender has a considerable effect on the HPgV recombination and HPgV viral dispersal across the region.

Materials and Methods {#sec002}
=====================

Ethics Statement {#sec003}
----------------

The patient samples were collected during October 2009 to November 2010, and this research plan was approved by the ethics committees of the Hubei Provincial Institute for Infectious Disease Control and Prevention. All the patients provided written consent, and the documents have been preserved by the ethics committee of Hubei Provincial Institute for Infectious Disease Control and Prevention.

Sample Collection, RNA Extraction, PCR and Sequencing {#sec004}
-----------------------------------------------------

HIV positive samples analyzed in this study were tested for the presence of HPgV RNA using primers from the 5′-UTR \[[@pone.0161880.ref013]\]. Twenty-three previously identified HIV/HPgV co-infection patients from 13 counties of Hubei province in China were enrolled in this study. Total RNA was extracted from 100 μl serum with Trizol LS reagents (Invitrogen, Carlsbad, California, USA) following the manufacturer's instructions. Reverse transcription was carried out with random hexamers primers (Promega, Madison, Wisconsin, USA), M-MLV reverse transcriptase (Promega, Madison, Wisconsin, USA), ribonuclease inhibitor (Biostar International, Canada) and 2 μg eluted RNA in a total volume of 25 μl for 60 min at 37°C, following a preheating step for 10 min at 70°C. The 906bp length sequences of HPgV covering partial E1 region and E2 region (positions 963--1868, corresponding to the GenBank accession: AF121950) was amplified using high fidelity DNA Polymerase Pyrobest (Takara, Japan). The amplification of E1-E2 region was performed by nested PCR using outer primers (E2_F: `5′-RGTGGGRRAGTGAGTTTTGGAGAT-3′` and E2_R1: `5′-RAACGTHCCRGTVGGAGGCT-3′`) and inner primers (E1fon: `5′-TGGGAAAGTGAGTTTTGGAGATGG-3′` and E2_R2: `5′-DTCYCGGATCTTGGTCATGG-3′`). The touchdown PCR reaction was initiated with a preheating procedure (95°C for 5 min) and performed for 30 cycles (the annealing temperature was progressively lowered from 65°C to 50°C by 1°C every cycle, followed by 15 additional cycles at 50°C) and a final extension cycle at 72°C for 10 min on a thermocycler. Subsequently, PCR products were extracted from the gel using the Easy Pure Quick Gel Extraction Kit (TransGen Biotech, Beijing, China) and then were TA-cloned into plasmid pTA2 vector using the Target CloneTM kit (Toyobo, Osaka, Japan) following the manufacturer's instructions. After an incubation period of 24 h on LB agar plates in the presence of 50 μg/ml ampicillin, the resultant clones were screened for the proper insert based on the color reaction using the Xgal-IPTG system. Nine to ten clones of each patient were randomly picked up for sequencing. Sequencing was carried out using the ABI-PRISM3730 sequencer in Sangon Biotechnology of China. All the sequences generated in this study were deposited in GenBank (accession numbers KU843606-KU843834). To evaluate the nucleotide variability originated from PCR error, a known sequence was PCR amplified, cloned, and sequenced under identical conditions. Ten independent clones were analyzed and showed absolute identity with the parental sequence.

Recombination Analysis {#sec005}
----------------------

Coding nucleotide sequences of the E1-E2 genomic region were aligned using the MUSCLE algorithm implemented in MEGA 7 \[[@pone.0161880.ref027]\]. Using the same program nucleotide diversity for each patient and the corresponding standard errors were also estimated. To detect the potential recombinant sequences in the dataset, we performed three independent analyses using the methods implemented in SplitsTree ver. 4 \[[@pone.0161880.ref028]\], RDP4 \[[@pone.0161880.ref029]\], and Simplot v3.5.1 programs \[[@pone.0161880.ref030]\]. SplitsTree ver. 4 is based on the well-established pairwise homoplasy test in conjunction with split-decomposition networks and was used to identify the presence of recombination in our dataset. Split networks were generated with the Neighbor Net algorithm and the pairwise homoplasy indexes (PHI) of the networks were calculated. An observed PHI value \< 0.05 indicated significant presence of recombination. The split networks generalize phylogenetic trees that allow the representation of conflicting signals or alternative evolutionary history, including recombination events. Putative recombinants are usually located at parallel edges in the network. By progressively removing sequences at the vertices, we would find which sequence could significantly increase the *p*-value by PHI test. Until the *p*-value was \> 0.05, sequences that are removed could be considered as putative recombinants.

Detection of potential recombinant sequences and putative breakpoint events were also carried out using the RDP, GENECONV, Maxchi, Chimaera, Siscan, and 3Seq algorithms implemented in RDP4 software package. Sequences are considered to be recombinant if the *p*-values \< 0.05 after Bonferroni correction for multiple tests. The breakpoint positions and recombinant sequences inferred for each detected potential recombination event were manually checked. The SimPlot v3.5.1 program was also used to identify the putative recombination breakpoints. The recombinants were confirmed using a boot-scanning analysis with 1000 bootstrap replicates. The window size and the step size were set to 200bp and 20bp, respectively. Statistical tests such as Fisher's exact test for categorical variables and Welch's two sample t-test for continuous variables were performed using R ver. 3.10 \[[@pone.0161880.ref031]\].

Phylogenetic Analysis {#sec006}
---------------------

The Maximum-likelihood (ML) tree was reconstructed under the appropriate nucleotide substitution model using the MEGA7 \[[@pone.0161880.ref027]\]. Using the same program, robustness of the tree was evaluated by the bootstrapping with 1000 replicates. To determine the genotype affiliation of each viral clone, reference sequences were retrieved from GenBank and were included in the phylogenetic analysis. A chimpanzee HPgV variant (SPgV~tro~) (GenBank accession: AF070476) was used as the outgroup. The best-fit model of nucleotide substitution was selected according to the Bayesian Information Criterion (BIC) implemented in MEGA7 \[[@pone.0161880.ref027]\]. The General Time Reversible (GTR) with invariable sites (I) and gamma distribution (Γ) parameter is the best-fit model. Additionally, to assess the robustness of ML tree topologies, we also estimated posterior probabilities for each node by performing BMCMC (Bayesian Markov Chain Monte Carlo) analyses implemented in MrBayes, version 3.1.2 \[[@pone.0161880.ref032]\]

Results {#sec007}
=======

HPgV Infection Status {#sec008}
---------------------

In the present study, a total of 229 clonal sequences, each with a nucleotide sequence length of 906-bp covering partial E1-E2 gene of HPgV, from 23 HIV/ HPgV co-infected patients (15 males; 8 females) with the ages ranging from 24 to 58 years residing in the Hubei province of central China were analyzed. The number of clones, infection status, and viral transmission routes of each patient are listed in [Table 1](#pone.0161880.t001){ref-type="table"}. The 23 patients were tested as positive for HPgV RNA and negative for anti-E2 antibody. In addition, none of the patients were infected with HBV and HCV.

10.1371/journal.pone.0161880.t001

###### Number of patients, patient ID, transmission route, CD4 count, HIV viral load, number of clones, and Phi test for each patient analyzed in this study.

![](pone.0161880.t001){#pone.0161880.t001g}

  Patient ID[^a^](#t001fn001){ref-type="table-fn"}   Infection Route        Therapy     CD4       Viral Load[^b^](#t001fn002){ref-type="table-fn"}   Viral sequences   PHI Test   
  -------------------------------------------------- ---------------------- ----------- --------- -------------------------------------------------- ----------------- ---------- ------------------------------------------
  JYM_1                                              heterosexual           No          670       \<LDL                                              10                0          0.07865
  CBM_2                                              heterosexual           HAART       221       \<LDL                                              10                0          NI[^c^](#t001fn003){ref-type="table-fn"}
  QCF_3                                              paid blood donor       HAART       405       \<LDL                                              10                0          0.3697
  JZM_7                                              paid blood donor       No          429       UN                                                 10                0          1.0
  CBM_8                                              homosexual             No          594       UN                                                 10                0          0.03394
  QCM_9                                              heterosexual           No          16        13900                                              10                0          1.0
  XAM_10                                             heterosexual           HAART       255       \<LDL                                              10                0          1.0
  JZM_23                                             heterosexual           No          695       UN                                                 10                0          1.0
  **XAM_27**                                         **homosexual**         **No**      **36**    **3030**                                           **10**            **4**      **0**
  **QCM_31**                                         **paid blood donor**   **HAART**   **261**   **\<LDL**                                          **10**            **7**      **0**
  **QCM_32**                                         **heterosexual**       **HAART**   **259**   **\<LDL**                                          **10**            **1**      **0.581**
  CBF_33                                             intravenous drug       No          49        178                                                10                0          1.0
  QCF_34                                             paid blood donor       HAART       411       \<LDL                                              10                0          NI
  QCF_35                                             heterosexual           HAART       193       \<LDL                                              10                0          0.1103
  CYM_36                                             heterosexual           No          369       UN                                                 9                 0          1.0
  **TSF_37**                                         **heterosexual**       **HAART**   **188**   **\<LDL**                                          **10**            **5**      **0**
  CYF_38                                             heterosexual           HAART       366       \<LDL                                              10                0          1.0
  **JZM_39**                                         **homosexual**         **HAART**   **373**   **\<LDL**                                          **10**            **4**      **0**
  **CYM_40**                                         **heterosexual**       **No**      **238**   **UN**                                             **10**            **1**      **NI**
  CYF_41                                             heterosexual           HAART       318       \<LDL                                              10                0          1.0
  JZM_46                                             homosexual             HAART       345       \<LDL                                              10                0          NI
  TCF_55                                             heterosexual           HAART       296       \<LDL                                              10                0          0.4319
  JZM_58                                             heterosexual           HAART       407       \<LDL                                              10                0          0.007965

^a^The nomenclature of patients. The first two letters represent sampling locations; the last letter represents the gender of each patient: M for male and F for female; the numeric represent patients\' code.

^b^HIV viral load (RNA copies/ml); UN: undection; \<LDL: below the lower detection limit.

^c^There are too few informative characters to use the Phi Test as implemented here.

Patients with recombinant sequences are in bold.

Within-Host Genetic Recombination and Phylogenetic Analysis {#sec009}
-----------------------------------------------------------

A split network was initially constructed using all the 229 sequences ([Fig 1A](#pone.0161880.g001){ref-type="fig"}). These sequences fall into eleven major divergent clades (clades: 1--11) and exhibited a reticulate topology ([Fig 1A](#pone.0161880.g001){ref-type="fig"}). Some sequences from patients XAM_27, QCM_31, JZM_39, TSF_37, CYM_40 and QCM_32 emerged as outliers and formed branches of the major clades ([Fig 1A](#pone.0161880.g001){ref-type="fig"}), thus indicating the presence of recombinant sequences. After exclusion of these potential recombinant sequences (i.e., the branches), which yielded conflicting phylogenetic signals, a new split network was constructed to illustrate the evolutionary relationships among the clades ([Fig 1B](#pone.0161880.g001){ref-type="fig"}). Consistently, the new network also revealed the same number of clades (clades: 1--11, [Fig 1B](#pone.0161880.g001){ref-type="fig"}), however, with no statistical significance for recombination (*p* \> 0.05). In contrast to the reticulate topology ([Fig 1A](#pone.0161880.g001){ref-type="fig"}), the new network showed a star-like topology ([Fig 1B](#pone.0161880.g001){ref-type="fig"}). Consistently, the ML ([Fig 2](#pone.0161880.g002){ref-type="fig"}) and the Bayesian ([S1 Fig](#pone.0161880.s001){ref-type="supplementary-material"}) phylogenies also revealed the presence of 11 clades. Our analyses revealed that while nine clades that comprised of clonal sequences, mostly from 21 patients, belonged to HPgV genotype 3, two clades that comprised of clonal sequences from two patients belonged to genotype 2 ([Fig 2](#pone.0161880.g002){ref-type="fig"}). The sequence JZM39_5 formed a novel clade (Figs [1](#pone.0161880.g001){ref-type="fig"} and [2](#pone.0161880.g002){ref-type="fig"}).

![Phylogenetic networks of HPgV E1-E2 segments.\
(**A**) A split network, including all sequences, was first constructed. The sequences clustered in eleven clades designated 1 to 11. The outliers are classified as putative intra-subtype recombinants (in red) or a novel clade (in black). (**B**) Sequences inferring conflicting phylogenetic signals were excluded (recombinant candidates) were removed, and a new split network was constructed.](pone.0161880.g001){#pone.0161880.g001}

![Maximum likelihood tree depicting two and nine clades belong to genotype 2 and genotype 3, respectively.\
Nodes with bootstrap values \> 70 are mentioned at the base of the nodes. Recombinant sequences were excluded from the analyses. Clades that were recovered in the present study are shown in different colors. GenBank reference sequences representing genotypes 1 to 5 are included in the analyses.](pone.0161880.g002){#pone.0161880.g002}

To further define the putative recombination signals as observed by PHI test, we also analyzed the data using the distance-based methods implemented in recombination detection program RDP4 ([Table 2](#pone.0161880.t002){ref-type="table"}) and SimPlot ([S2 Fig](#pone.0161880.s002){ref-type="supplementary-material"}). Consistent with the split network results ([Fig 1A](#pone.0161880.g001){ref-type="fig"}), RDP4 also showed strong evidence of recombination events and were detected in the same six patients (i.e., patients XAM_27, QCM_31, JZM_39, TSF_37, CYM_40 and QCM_32). Interestingly, five of the six patients were male. Based on these results, it appears that genetic recombination may occur more frequently in male patients than the female patients; however, due to limited sample size, this result should be interpreted with caution. Most of the deduced parental recombinant sequences belonged to clades 1, 2 and 8 ([Table 2](#pone.0161880.t002){ref-type="table"}). With the exception of few clades (clades: 1, 2 and 8), most of the clades are represented by the clonal sequences of female patients with no evidence of sharing of the sequences among these female patients ([Table 3](#pone.0161880.t003){ref-type="table"}). In contrast, while clade 1 and 8 shared sequences among the male patients, clade 2 shared the sequences between male and female patients ([Table 3](#pone.0161880.t003){ref-type="table"}). Altogether, these results clearly indicate co-circulation of phylogenetically distinct strains, and therefore, indicating the possibility of inter-clade recombination within each patient.

10.1371/journal.pone.0161880.t002

###### Summary of unique recombination events identified by RDP4 program.

![](pone.0161880.t002){#pone.0161880.t002g}

  Patient ID   Recombination Event Number   Breakpoint Positions                            Recombinant Sequences   Minor Parental Sequence(s)   Major Parental Sequence(s)[^a^](#t002fn001){ref-type="table-fn"}   Detection Methods                                               
  ------------ ---------------------------- ----------------------------------------------- ----------------------- ---------------------------- ------------------------------------------------------------------ ------------------- ---------- ---------- ---------- ---------- ----------
  XAM_27       1                            468--720                                        XAM27_4                 XAM27_2/3/5/9(clade 8)       XAM27_7/8(clade 5)                                                 \-                  9.39E-10   7.52E-10   4.46E-10   8.22E-10   7.74E-21
               2                            242--742                                        XAM27_1                 XAM27_7/8(clade 5)           XAM27_2/3/5/9(clade 8)                                             \-                  3.00E-04   2.33E-09   2.33E-09   1.03E-12   1.53E-16
               3                            342--516                                        XAM27_10                XAM27_7/8(clade 5)           XAM27_2/3/5/9(clade 8)                                             \-                  1.25E-02   2.11E-02   \-         \-         1.32E-07
               4                            742--884                                        XAM27_6                 XAM27_2/3/5/9(clade 8)       XAM27_7/8(clade 5)                                                 \-                  9.20E-04   2.67E-02   \-         \-         5.72E-05
  JZM_39       1                            592--701                                        JZM39_3                 JZM39_5                      JZM39_1/2/6/7/9(clade 8)                                           6.24E-05            1.15E-05   5.84E-09   1.94E-08   1.30E-09   4.82E-10
               2                            358--742                                        JZM39_3/10              JZM39_8(clade 2)             JZM39_1/2/6/7/9(clade 8)                                           \-                  6.81E-05   1.73E-10   7.97E-09   8.01E-14   1.68E-16
               3                            376--814[\*](#t002fn003){ref-type="table-fn"}   JZM39_4                 JZM39_5                      JZM39_1/2/6/7/9(clade 8)                                           \-                  2.79E-05   1.62E-05   1.53E-05   8.29E-07   8.63E-11
               4                            1--178                                          JZM39_8                 JZM39_1/2/6/7/9(clade 8)     clade 2                                                            2.60E-06            \-         5.04E-07   4.34E-04   1.45E-19   8.76E-12
  QCM_31       1                            430--745                                        QCM31_3                 QCM31_4/10(clade 8)          QCM31_6(clade 2)                                                   1.68E-07            2.41E-06   9.01E-10   1.28E-10   6.42E-10   1.19E-20
               2                            516--662                                        QCM31_7                 QCM31_6(clade 2)             QCM31_4/10(clade 8)                                                8.84E-12            4.44E-10   5.88E-07   4.84E-07   5.17E-09   1.76E-15
               3                            70--309                                         QCM31_2/8               QCM31_4/10(clade 8)          QCM31_6(clade 2)                                                   2.78E-03            8.09E-06   8.97E-10   5.65E-07   \-         1.57E-14
               4                            69[\*](#t002fn003){ref-type="table-fn"}-682     QCM31_1/9               QCM31_6(clade 2)             QCM31_4/10(clade 8)                                                \-                  7.78E-05   4.00E-04   1.11E-03   \-         3.12E-11
               5                            544--780                                        QCM31_11                QCM31_6(clade 2)             QCM31_4/10(clade 8)                                                7.78E-07            5.83E-06   1.37E-09   1.75E-07   8.31E-03   5.14E-14
               6                            508--701                                        QCM31_8                 JZM39_5                      QCM31_6(clade 2)                                                   \-                  2.62E-03   1.41E-05   1.30E-05   7.82E-07   1.36E-08
  TSF_37       1                            72[\*](#t002fn003){ref-type="table-fn"}-187     TSF37_2                 TSF37_1/4/5/8(clade 2)       TSF37_7(clade 1)                                                   \-                  8.89E-05   \-         \-         1.98E-13   2.27E-07
               2                            574--853[\*](#t002fn003){ref-type="table-fn"}   TSF37_3                 TSF37_7(clade 1)             TSF37_1/4/5/8(clade 2)                                             \-                  5.47E-05   7.70E-08   1.52E-07   5.41E-08   5.02E-14
               3                            3--259[\*](#t002fn003){ref-type="table-fn"}     TSF37_6                 TSF37_1/4/5/8(clade 2)       TSF37_7(clade 1)                                                   \-                  1.72E-02   \-         \-         \-         4.36E-08
               4                            770--865                                        TSF37_9                 TSF37_7 (clade 1)            TSF37_4(clade 2)                                                   \-                  2.40E-02   1.91E-04   1.50E-02   \-         3.97E-10
               5                            648--870                                        TSF37_2/10              TSF37_1/4/5/8(clade 2)       TSF37_7(clade 1)                                                   \-                  3.57E-08   1.47E-04   1.47E-04   \-         1.12E-12
  CYM_40       1                            502--682[\*](#t002fn003){ref-type="table-fn"}   CYM40_8                 clade 2                      CYM40_X(clade 1)                                                   \-                  1.49E-05   1.80E-05   1.80E-05   \-         1.08E-11
  QCM_32       1                            180--363                                        QCM32_5                 Unknown                      QCM32_X(clade 6)                                                   \-                  \-         3.27E-02   \-         6.60E-13   1.29E-02

\* = The actual breakpoint position is undetermined (it was most likely overprinted by a subsequent recombination event).

\- = No significant P-value was recorded for this recombination event using this method.

^a^ X = The remaining non-recombination sequences of the patient.

10.1371/journal.pone.0161880.t003

###### The number of sequences shared by the patients for a given clade after the exclusion of recombinant sequences.
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  Patient ID   Genotype 3   Genotype 2                                       
  ------------ ------------ ------------ ---- ---- --- --- ---- --- --- ---- ----
  JYM_1        8                                                1            
  CBM_2        10                                                            
  JZM_7        10                                                            
  CBM_8        10                                                            
  QCM_9        8                         2                                   
  XAM_10       9            1                                                
  **CYM_40**   9                                                             
  CBF_33                    10                                               
  QCF_34                    10                                               
  QCF_35                    10                                               
  **TSF_37**   1            4                                                
  TCF_55                                 10                                  
  CYF_38                                      10                             
  JZM_58       2                              8                              
  **XZM_27**                                       5            2            
  **QCM_32**                                           9                     
  CYF_41                                                   10                
  **JZM_39**                                                    5            
  JZM_46       1                                                9            
  **QCM_31**                1                                   2            
  CYM_36                    2                                       7        
  JZM_23                                                                10   
  QCF_3                                                                      10

Patients with recombinant sequences are in bold.

If all the viral clones within each patient have a single origin, these clones are expected to exhibit patient-specific clustering \[[@pone.0161880.ref013]\]. Therefore, the observation of such patient-specific clustering was also expected in some patients ([Fig 1](#pone.0161880.g001){ref-type="fig"} and [Table 3](#pone.0161880.t003){ref-type="table"}). However, sequences from ten patients (9 males *vs* 1 female) still appeared to be non-monophyletic and are shared among the patients, including the four recombinant patients XAM_27, QCM_31, JZM_39 and TSF_37. Interestingly, the nucleotide diversity of HPgV in each of these four patients is relatively higher than the other patients (black bar in [Fig 3](#pone.0161880.g003){ref-type="fig"}; *p* \<0.01), implying that recombination played an important role in shaping HPgV diversity. Additionally, the other six patients who were infected with viral strains representing multiple clades of HPgV ([Table 3](#pone.0161880.t003){ref-type="table"}) also have a relative higher nucleotide diversity (grey bar in [Fig 3](#pone.0161880.g003){ref-type="fig"}; *p* \< 0.0001), which indicates the co-circulation of viral strains representing multiple clades.

![Nucleotide diversity of each patient.\
The bar plots for each individual (**A**) and patient-specific group (**B**) show a relatively higher intra-host nucleotide diversity in patients detected with recombination sequences (black) or/and infected with multiple variants (grey) than other patients (white). Nucleotide diversity was evaluated regardless of recombination.](pone.0161880.g003){#pone.0161880.g003}

Discussion {#sec010}
==========

Genetic recombination, more importantly in (+) ss RNA viruses, played a dominant role in the emergence of new viral strains with new genetic makeup and greater fitness \[[@pone.0161880.ref033]\]. Knowledge of the recombination mechanisms, host-factors, as well as their putative roles in the emergence divergent HPgV strains, especially in the HIV co-infected individuals, would provide important insights into the understanding of within-host viral evolution. In this study, we report the evidence of intra-genotypic recombination events that are likely to play the dominant role in generating high within-host HPgV genetic diversity. Although HPgV E1-E2 glycoprotein genomic region is constrained by purifying selection \[[@pone.0161880.ref013]\] and also the viral genome is characterized by the presence of abundant RNA secondary structure motifs \[[@pone.0161880.ref034], [@pone.0161880.ref035]\], recombination can potentially acquire genetic diversity by generating combinations of preexisting nucleotide polymorphisms, and recombination could also act to shuffle the partial or entire RNA secondary structure region to accelerate the process. Consistent with the results of the present study, previous studies have reported that genetic recombination is the likely cause for the observation of the phylogenetic incongruence among the subgenomic regions of HPgV \[[@pone.0161880.ref036], [@pone.0161880.ref037]\], thus suggesting that genetic recombination has a profound influence on the genomic architecture of HPgV.

Further, our results also provide the evidence of within-host (predominantly in male patients) inter-clade recombination between the divergent strains of HPgV belonging to genotype 3. The presence of divergent strains of HPgV indicates that these patients might have been infected with the HPgV strains multiple times. Given the same transmission routes as HIV, having multiple sexual partners with unprotected sex may increase the chance of being infected with multiple yet divergent strains of HPgV \[[@pone.0161880.ref038]\]. It may be possible that individual patients might have acquired HPgV strains multiple times through sexual contacts even prior to infection with HIV. Taken together, multiple infections with divergent HPgV viral strains and within-host genetic recombination, could be the major drivers in shaping genetic diversity of HPgV, and also might have contributed to the remarkable population growth of HPgV strains within each HIV/HPgV co-infected host \[[@pone.0161880.ref013]\].

Males and females inherently differed in their susceptibility, multiplicity infection and virus diversity to a variety of DNA and RNA viruses \[[@pone.0161880.ref039]--[@pone.0161880.ref041]\]. Previous studies reported that biological and genetic differences in immune responses and exposure to viruses may contribute to the gender-bias susceptibility \[[@pone.0161880.ref042], [@pone.0161880.ref043]\]. In this study, five of the six patients who had recombinant sequences were male. However, due to limited sample size, we could not draw a conclusion as to whether a patient's gender played an important role in HPgV recombination. Interestingly, previous studies have reported the male-dominant prevalence of HPgV \[[@pone.0161880.ref044]\]. High risk behaviors, such as male-to-male sex (MSM), are also likely to be associated with a high prevalence of persistent HPgV infection \[[@pone.0161880.ref009], [@pone.0161880.ref045]\]. Although the data may greatly vary according to geographic regions and social culture, males seem to have higher incidence of high-risk sexual exposure than females \[[@pone.0161880.ref046], [@pone.0161880.ref047]\]. To some extent, this pattern is also consistent with the available statistical data, for instance, statistics from the National Survey of Family Growth (NSFG) (available at: <http://www.cdc.gov/nchs/nsfg/key_statistics/n.htm>).

Collectively, our study provides evidence of within-host genetic recombination in HPgV in HIV co-infected individuals, and also suggests that infection with multiple variants dramatically increases the overall viral diversity. While the biological consequences of viral diversity and recombination of HPgV have not been examined, studies of HIV and HCV suggest that viral diversity and recombination may result in altered cell tropism, virulence, immune evasion and drug resistance/sensitivity \[[@pone.0161880.ref048]--[@pone.0161880.ref051]\]. Nevertheless, the present study indicates that the observation of male-dominant recombination patterns and high HPgV viral diversities may likely be associated with the higher incidence of high-risk sexual exposure of the male patients. However, due to the limited sample size, the inference of the male-dominant recombination patterns should be taken with caution. Further study with larger cohorts of samples is required to validate the male-dominant recombination patterns as observed in the present study.

Supporting Information {#sec011}
======================

###### Bayesian phylogeny depicting two and nine clades belonged to genotype 2 and genotype 3, respectively.

Nodes with posterior probabilities \> 0.9 are mentioned at the base of the nodes. Recombinant sequences were excluded from the analyses. Clades that were recovered in the present study are shown in different colors. GenBank reference sequences representing genotypes 1 to 5 are included in the analyses.

(TIF)

###### 

Click here for additional data file.

###### SimPlot analysis for the HPgV E1-E2 segments.

The bootscanning plot was carried out on each putative recombinant. The parameters used for analysis are shown on the bottom row of each figure. The QCM32_5 was not included in the bootscanning analysis for the unidentified minor parental sequences.

(ZIP)

###### 

Click here for additional data file.
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